Literature DB >> 22654271

Hepatic radioembolization complicated by gastrointestinal ulceration.

Jeremy Collins1, Riad Salem.   

Abstract

Gastric ulceration is a relatively uncommon but well-described complication of yttrium 90 (Y90) radioembolization therapy in the locoregional treatment of hepatic tumors. Meticulous attention to vascular anatomy, an assessment of antegrade hepatic arterial flow, and knowledge of the dynamic embolic effect of the chosen Y90 particulate at treatment are requirements to reduce the risk of nontarget embolization to gastrointestinal structures. Radiation-associated gastrointestinal ulceration is difficult to treat, and may be associated with gastrointestinal bleeding, bowel obstruction, and perforation. Surgical excision of the involved segment with bypass may be necessary. The increased use of coil embolization of at-risk vessels combined with administration of Y90 particulates with minimal embolic effect has reduced the incidence of radioembolization associated gastrointestinal ulceration.

Entities:  

Keywords:  Radioembolization; complication; ulceration

Year:  2011        PMID: 22654271      PMCID: PMC3193333          DOI: 10.1055/s-0031-1280673

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  10 in total

1.  Gastroduodenal injury after radioembolization of hepatic tumors.

Authors:  Cristina Carretero; Miguel Munoz-Navas; Maite Betes; Ramon Angos; Jose C Subtil; Ignacio Fernandez-Urien; Susana De la Riva; Josu Sola; Jose I Bilbao; Esther de Luis; Bruno Sangro
Journal:  Am J Gastroenterol       Date:  2007-03-13       Impact factor: 10.864

Review 2.  Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review.

Authors:  Ahsun Riaz; Robert J Lewandowski; Laura M Kulik; Mary F Mulcahy; Kent T Sato; Robert K Ryu; Reed A Omary; Riad Salem
Journal:  J Vasc Interv Radiol       Date:  2009-07-29       Impact factor: 3.464

Review 3.  Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics.

Authors:  Riad Salem; Kenneth G Thurston
Journal:  J Vasc Interv Radiol       Date:  2006-09       Impact factor: 3.464

4.  Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience.

Authors:  Andrew S Kennedy; Douglas Coldwell; Charles Nutting; Ravi Murthy; Daniel E Wertman; Stephen P Loehr; Carroll Overton; Steven Meranze; Jerry Niedzwiecki; Scott Sailer
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-01       Impact factor: 7.038

5.  Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres.

Authors:  Teresa Szyszko; Adil Al-Nahhas; Paul Tait; D Rubello; Ruben Canelo; Nagy Habib; Long Jiao; Harpreet Wasan; D Bansi; A Thillainayagam; K Nijran; G Stamp; E O'Rourke
Journal:  Nucl Med Commun       Date:  2007-01       Impact factor: 1.690

6.  Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients.

Authors:  Brian I Carr
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

7.  Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere).

Authors:  Jennifer Steel; Andrew Baum; Brian Carr
Journal:  Psychooncology       Date:  2004-02       Impact factor: 3.894

8.  Treatment of liver tumors with yttrium-90 microspheres alone.

Authors:  R J Blanchard; I M Morrow; J B Sutherland
Journal:  Can Assoc Radiol J       Date:  1989-08       Impact factor: 2.248

9.  Gastrointestinal complications associated with hepatic arterial Yttrium-90 microsphere therapy.

Authors:  Ravi Murthy; Daniel B Brown; Riad Salem; Steven G Meranze; Douglas M Coldwell; Sunil Krishnan; Rodolfo Nunez; Amit Habbu; David Liu; William Ross; Alan M Cohen; Michael Censullo
Journal:  J Vasc Interv Radiol       Date:  2007-04       Impact factor: 3.464

10.  Yttrium-90 microsphere induced gastrointestinal tract ulceration.

Authors:  Christopher D South; Marty M Meyer; Gregory Meis; Edward Y Kim; Fred B Thomas; Ali A Rikabi; Hooman Khabiri; Mark Bloomston
Journal:  World J Surg Oncol       Date:  2008-09-02       Impact factor: 2.754

  10 in total
  6 in total

Review 1.  Recognizing and Managing Adverse Events in Y-90 Radioembolization.

Authors:  Grace L Laidlaw; Guy E Johnson
Journal:  Semin Intervent Radiol       Date:  2021-10-07       Impact factor: 1.780

Review 2.  Theranostic Imaging of Yttrium-90.

Authors:  Chadwick L Wright; Jun Zhang; Michael F Tweedle; Michael V Knopp; Nathan C Hall
Journal:  Biomed Res Int       Date:  2015-05-28       Impact factor: 3.411

3.  Gastrectomy for the treatment of refractory gastric ulceration after radioembolization with 90Y microspheres.

Authors:  Sun Young Yim; Jin Dong Kim; Jin Yong Jung; Chang Ha Kim; Yeon Seok Seo; Hyung Joon Yim; Soon Ho Um; Ho Sang Ryu; Yun Hwan Kim; Chong Suk Kim; Eun Shin
Journal:  Clin Mol Hepatol       Date:  2014-09-25

Review 4.  Role of C-arm cone-beam CT in chemoembolization for hepatocellular carcinoma.

Authors:  Hyo-Cheol Kim
Journal:  Korean J Radiol       Date:  2015-01-09       Impact factor: 3.500

5.  Long-Term Palliative Effect of Stenting in Gastric Outlet Obstruction Due to Transarterial Chemoembolization with Yttrium-90 in a Patient with Metastatic Neuroendocrine Tumor.

Authors:  Erkan Caglar; Gulen Doğusoy; Levent Kabasakal; Ahmet Dobrucali
Journal:  Clin Endosc       Date:  2016-06-29

6.  Sequential intra-arterial infusion of 90Y-resin microspheres and mitomycin C in chemo refractory liver metastatic breast cancer patients: a single centre pilot study.

Authors:  Brigitte Maximiliana Aarts; Elisabeth Geneviève Klompenhouwer; Raphaëla Carmen Dresen; Christophe Michel Albert Louis Omer Deroose; Regina Gien Hoa Beets-Tan; Kevin Punie; Patrick Neven; Hans Wildiers; Geert Maleux
Journal:  Radiol Oncol       Date:  2020-01-21       Impact factor: 2.991

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.